

# CITATION REPORT

List of articles citing

The value of patient reporting to the  
pharmacovigilance system: a systematic review

DOI: 10.1111/bcp.13098

British Journal of Clinical Pharmacology, 2017, 83, 227-246.

**Source:** <https://exaly.com/paper-pdf/67708390/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
120	Informativeness of patient initial reports of adverse drug reactions. Can it be improved by a pharmacovigilance centre?. <b>2017</b> , 73, 1009-1018		6
119	Patient Reporting in the EU: Analysis of EudraVigilance Data. <b>2017</b> , 40, 629-645		36
118	The Quality of Clinical Information in Adverse Drug Reaction Reports by Patients and Healthcare Professionals: A Retrospective Comparative Analysis. <b>2017</b> , 40, 607-614		41
117	[Comparative relevance of declaration of side effects by patients and health professionals]. <b>2017</b> , 72, 625-633		4
116	Comment on "Patient Reporting in the EU: Analysis of EudraVigilance Data". <b>2017</b> , 40, 935-936		1
115	The value of patient reporting to the pharmacovigilance system: a systematic review. <i>British Journal of Clinical Pharmacology</i> , <b>2017</b> , 83, 227-246	3.8	83
114	Adverse drug reactions reported to the drug and poison information center of Tehran, Iran. <b>2017</b> , 12, e0185450		4
113	Three case reports of involuntary muscular movements as adverse reactions to sacubitril/valsartan. <i>British Journal of Clinical Pharmacology</i> , <b>2018</b> , 84, 1072-1074	3.8	5
112	Key pharmacovigilance stakeholders' experiences of direct patient reporting of adverse drug reactions and their prospects of future development in the European Union. <b>2018</b> , 155, 119-128		6
111	Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study): study protocol for a randomized controlled trial. <b>2018</b> , 19, 174		8
110	Knowledge of Adverse Drug Reaction Reporting and the Pharmacovigilance of Biological Medicines: A Survey of Healthcare Professionals in Ireland. <b>2018</b> , 32, 267-280		15
109	Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012. <b>2018</b> , 8, e019759		13
108	Public engagement and the role of the media in post-marketing drug safety: the case of Eltroxin <sup>®</sup> (levothyroxine) in New Zealand. <b>2018</b> , 28, 388-401		4
107	Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre. <b>2018</b> , 41, 203-212		29
106	Exploring sociodemographic and economic factors that promote adverse drug reactions reporting by patients. <b>2018</b> , 122, 263-268		5
105	Methods to Compare Adverse Events in Twitter to FAERS, Drug Information Databases, and Systematic Reviews: Proof of Concept with Adalimumab. <b>2018</b> , 41, 1397-1410		20
104	Current trends in pharmacovigilance: value and gaps of patient reporting. <b>2018</b> , 40, 754-757		4

103	Spontaneous Reporting on Adverse Events by Consumers in the United States: An Analysis of the Food and Drug Administration Adverse Event Reporting System Database. <b>2018</b> , 5, 117-128	21
102	Spontaneous Reporting of Adverse Drug Reactions by Consumers in Comparison with Healthcare Professionals in Turkey from 2014 to 2016. <b>2018</b> , 32, 353-364	3
101	Potential negative impact of informing patients about medication side effects: a systematic review. <b>2018</b> , 40, 806-822	10
100	Impact of a New Consumer Form on the Quantity and Quality of Adverse Event Reports Submitted to the United States Food and Drug Administration. <b>2019</b> , 39, 1042-1052	3
99	Postmarketing Spontaneous Pharmacovigilance Reporting Systems. <b>2019</b> , 165-201	4
98	Making medicines safer: analysis of patient reports to the UK's Yellow Card Scheme. <b>2019</b> , 18, 1237-1243	2
97	Intensive Monitoring Studies for Assessing Medicines: A Systematic Review. <b>2019</b> , 6, 147	1
96	Proton pump inhibitors therapy and the risk of pneumonia: a systematic review and meta-analysis of randomized controlled trials and observational studies. <b>2019</b> , 18, 163-172	30
95	Hypersensitivity Reactions in Serious Adverse Events Reported for Paracetamol in the EudraVigilance Database, 2007-2018. <b>2019</b> , 7,	1
94	The effect of community dialogues and sensitization on patient reporting of adverse events in rural Uganda: Uncontrolled before-after study. <b>2019</b> , 14, e0203721	2
93	Adverse events reported for Mirena levonorgestrel-releasing intrauterine device in France and impact of media coverage. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 2126-2133	3.8 5
92	Knowledge, awareness, perception and reporting of experienced adverse drug reactions among outpatients in Nigeria. <b>2019</b> , 41, 1062-1073	4
91	Pharmacovigilance as Scientific Discovery: An Argument for Trans-Disciplinarity. <b>2019</b> , 42, 1115-1124	13
90	Fifteen years of patient reporting -what have we learned and where are we heading to?. <b>2019</b> , 18, 477-484	7
89	Home-based Anti-Tuberculosis Treatment Adverse Reactions (HATTAR) study: a protocol for a prospective observational study. <b>2019</b> , 9, e027321	3
88	Harnessing social media data for pharmacovigilance: a review of current state of the art, challenges and future directions. <b>2019</b> , 8, 113-135	25
87	Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System. <b>2019</b> , 14, 205-221	54
86	Use of a Patient-Friendly Terms List in the Adverse Drug Reaction Report Form: A Database Study. <b>2019</b> , 42, 881-886	3

85	Moving forward from drug-centred to patient-centred research: A white paper initiated by EORTC and developed together with the BioMed Alliance members. <b>2019</b> , 53,	7
84	Evolving Roles of Spontaneous Reporting Systems to Assess and Monitor Drug Safety. <b>2019</b> ,	7
83	Intensive monitoring of adverse drug events associated with the use of new glucose-lowering drugs: results from an inception cohort study in Portugal. <b>2020</b> , 37, 648-656	2
82	Severe Cutaneous Adverse Drug Reactions Associated with Allopurinol: An Analysis of Spontaneous Reporting System in Southern Italy. <b>2020</b> , 7, 41-51	8
81	Public Awareness about Medicine Information, Safety, and Adverse Drug Reaction (ADR) Reporting in Dammam, Saudi Arabia. <b>2020</b> , 8,	0
80	Reader response: Reducing birth defects in women with epilepsy: Research leading to results. <b>2020</b> , 95, 188-189	1
79	A cross-sectional survey of knowledge, attitude, and willingness to engage in spontaneous reporting of adverse drug reactions by Korean consumers. <b>2020</b> , 20, 1527	5
78	Patient literacy and awareness of medicine safety. <b>2020</b> , 28, 552-560	3
77	Ten years of vaccinovigilance in Italy: an overview of the pharmacovigilance data from 2008 to 2017. <b>2020</b> , 10, 14122	1
76	Preliminary Results of the FASM Study, an On-Going Italian Active Pharmacovigilance Project. <b>2020</b> , 13,	1
75	Patients with inflammatory rheumatic diseases: quality of self-reported medical information in a prospective cohort event monitoring system. <b>2020</b> , 59, 1253-1261	11
74	Pharmacovigilance of anti-cancer medicines: opportunities and challenges. <b>2020</b> , 19, 849-860	2
73	Analysis of antiseizure drug-related adverse reactions from the electronic health record using the common data model. <b>2020</b> , 61, 610-616	12
72	Physicians' Understanding and Practices of Pharmacovigilance: Qualitative Experience from A Lower Middle-Income Country. <b>2020</b> , 17,	9
71	Adverse Drug Reaction Reporting Using a Mobile Device Application by Persons with Multiple Sclerosis: A Cluster Randomized Controlled Trial. <b>2021</b> , 44, 223-233	3
70	HaemoKBS: A knowledge-based system for real-time, continuous categorisation of adverse reactions in blood recipients. <b>2021</b> , 423, 756-767	
69	Patients' contribution to drug safety in Catalonia: the interest of personal feelings on adverse drug reactions. <b>2021</b> , 77, 637-642	1
68	Patient-Reported Adverse Events of Radiopharmaceuticals: A Prospective Study of 1002 Patients. <b>2021</b> , 44, 211-222	0

67	Direct reporting of adverse drug reactions by healthcare consumers in Africa: a narrative review. <b>2021</b> , 43, 11-24	
66	Tramadol-induced hiccups: a case-noncase study in the European pharmacovigilance database. <b>2021</b> , 12, 20420986211021230	1
65	Adverse Drug Reaction Reporting by Patients in 12 European Countries. <b>2021</b> , 18,	4
64	Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice. <b>2021</b> , 77, 1225-1234	2
63	Global COVID-19 pandemic and reporting behavior - An analysis of the Food and Drug Administration adverse events reporting system. <b>2021</b> , 30, 707-715	3
62	Adverse Drug Reaction Reports Regarding Abnormal Behavior After Oseltamivir Use in Children as Reported by Consumers or Healthcare Professionals. <b>2021</b> , 15, 533-541	
61	Understanding Patient Needs Regarding Adverse Drug Reaction Reporting Smartphone Applications: A Qualitative Insight from Saudi Arabia. <b>2021</b> , 18,	2
60	Active Extraction of Experience of Adverse Drug Reactions in Children. <b>2021</b> , 26, 352-360	
59	The potential of training specialist oncology nurses in real-life reporting of adverse drug reactions. <b>2021</b> , 77, 1531-1542	2
58	Impact of mobile health application on data collection and self-management of epilepsy. <b>2021</b> , 119, 107982	3
57	A patient-centred web-based adverse drug reaction reporting system identifies not yet labelled potential safety issues. <b>2021</b> , 77, 1697-1704	0
56	Current Status and Challenges of the System for Adverse Drug Reaction Reporting from Patients and Consumers in Japan: A Comparison with the Situation in Europe. <b>2021</b> , 52, 117-125	2
55	Motives to Report Adverse Drug Reactions to the National Agency: A Survey Study among Healthcare Professionals and Patients in Croatia, The Netherlands, and the UK. <b>2021</b> , 44, 1073-1083	1
54	Drug-Related Deaths in a Tertiary Hospital: Characteristics of Spontaneously Reported Cases and Comparison to Cases Detected from a Retrospective Study. <b>2021</b> , 10,	1
53	Patient and caregiver factors in ambulatory incident reports: a mixed-methods analysis. <b>2021</b> , 10,	0
52	PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudragilance Database. <b>2021</b> , 44, 337-349	10
51	Adverse Skin Reactions with Antiepileptic Drugs Using Korea Adverse Event Reporting System Database, 2008-2017. <b>2020</b> , 35, e17	9
50	Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System. <b>2021</b> , 1	0

49	"ADR PvPI" Android mobile app: Report adverse drug reaction at any time anywhere in India. <b>2019</b> , 51, 236-242		6
48	Recent changes in the pharmacovigilance system in the Russian Federation and the EAEU. <b>2019</b> , 12, 86-90		6
47	Features of International and Regional Pharmacovigilance Systems. <b>2020</b> , 28, 571-597		0
46	Pharmacovigilance. <b>2020</b> , 1-15		
45	A comparative study of active and passive adverse drug reaction reporting systems in terms of false reporting rate. <b>2020</b> , 51, 223-230		
44	Adverse Drug Reaction Reporting by Patients: Experience of 12 European Countries.		
43	Adverse Drug Reaction Reporting by Patients: Experience of 12 European Countries.		
42	Are Dental Patients Concerned About Safety? An Exploratory Study. <b>2020</b> , 20, 101424		1
41	Drug Induced Liver Injury: Perspective of the Adverse Drug Reaction Reports to the Portuguese Pharmacovigilance System from 2010 to 2019.. <b>2021</b> , 9,		0
40	Strengthening therapeutic adherence and pharmacovigilance to antimalarial treatment in Manaus, Brazil: a multicomponent strategy using mHealth.. <b>2022</b> , 21, 28		0
39	Areas of Interest and Social Consideration of Antidepressants on English Tweets: A Natural Language Processing Classification Study.. <b>2022</b> , 12,		1
38	Identifying and managing ADRs: Qualitative analysis of patient reports to the UK Yellow Card Scheme.. <i>British Journal of Clinical Pharmacology</i> , <b>2022</b> ,	3.8	
37	Pharmacovigilance in Low and Middle-Income Countries: A review with particular focus on Africa.. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> ,	3.8	3
36	Self-perceived versus physician documented adverse events in patients with multiple sclerosis REGIMS-a pharmacovigilance registry for patients with multiple sclerosis in Germany.. <b>2022</b> , 59, 103684		
35	Development of a web-based system to report medication-related adverse effects: a design and usability study (Preprint).		
34	Pharmacovigilance in China: Evolution and Future Challenges.. <i>British Journal of Clinical Pharmacology</i> , <b>2022</b> ,	3.8	1
33	Neurologists' Knowledge, Practice, and Attitudes towards Pharmacovigilance and Adverse Drug Reactions Reporting Process in Epileptic Patients-Comparative Analysis from Poland and Egypt.. <b>2022</b> , 19,		
32	A Clinical Practice Guideline for the Emergency Management of Anaphylaxis (2020).. <b>2022</b> , 13, 845689		0

31	Factors that Lead to Stagnation in Direct Patient Reporting of Adverse Drug Reactions: An Opinion Survey of the General Public and Physicians in Japan.. <b>2022</b> , 1		1
30	A cross-sectional study: comparison of public perceptions of adverse drug reaction reporting and monitoring in eastern and western China.. <b>2022</b> , 22, 318		1
29	Comparison of Patient Adverse Drug Reaction Reporting Systems in Nine Selected Countries.. <b>2022</b> , 19,		0
28	The Importance of Direct Patient Reporting of Adverse Drug Reactions in the Safety Monitoring Process.. <b>2021</b> , 19,		1
27	Data_Sheet_1.docx. <b>2019</b> ,		
26	Analysis of adverse drug events as a way to improve cancer patient care.. <b>2022</b> ,		
25	Implementation of a peer support intervention to promote the detection, reporting and management of adverse drug reactions in people living with HIV in Uganda: a protocol for a quasi-experimental study.. <b>2022</b> , 12, e056039		
24	Engaging Patients via Online Healthcare Fora: Three Pharmacovigilance Use Cases. 13,		0
23	A Qualitative Study of Stakeholders' Views on Pharmacovigilance System, Policy, and Coordination in Pakistan. 13,		0
22	Pharmacovigilance reporting during Seasonal Malaria Chemoprevention in Nigeria: Findings from the 2020 campaign.. <b>2022</b> , e01283		
21	Spontaneous Adverse Event Reporting by COVID-19 Vaccinated Healthcare Professionals Through an Electronic Form Implemented by the Hospital Pharmacy. 001857872211117		1
20	Historical profile will tell? A deep learning-based multi-level embedding framework for adverse drug event detection and extraction. <i>Decision Support Systems</i> , <b>2022</b> , 160, 113832	5.6	
19	Reported congenital malformations after exposure to non-tumour necrosis factor inhibitor biologics : a retrospective comparative study in EudraVigilance. <i>British Journal of Clinical Pharmacology</i> ,	3.8	0
18	Factors Contributing to Best Practices for Patient Involvement in Pharmacovigilance in Europe: A Stakeholder Analysis.		
17	Patient engagement in Pharmacovigilance: determinants and evolution of reporting from 2011 to 2020 in France.		
16	Mobile apps for quick adverse drug reaction report: a scoping review.		0
15	Development of a web-based system to report medication-related adverse effects: a design and usability study (Preprint).		0
14	Identifying medications underlying communication atypicalities in psychotic and affective disorders: A pharmacosurveillance study within the FDA Adverse Event Reporting System.		0

- 13 Quality of Active versus Spontaneous Reporting of Adverse Drug Reactions in Pediatric Patients: Relevance for Pharmacovigilance and Knowledge in Pediatric Medical Care. **2022**, 15, 1148 ○
- 12 Underreporting and Triggering Factors for Reporting ADRs of Two Ophthalmic Drugs: A Comparison between Spontaneous Reports and Active Pharmacovigilance Databases. **2022**, 10, 2182 ○
- 11 Pharmacovigilance. **2022**, 85-99 ○
- 10 Patients' Perception of the pharmacovigilance system: A pre-diagnostic and post-interventional cross-sectional survey. 13, ○
- 9 Pharmacists' role in detection and evaluation of adverse drug reactions: Developing proactive systems for pharmacosurveillance. ○
- 8 Dilemma of belimumab therapy (dis)continuation during pregnancy: Results of a retrospective study in eudravigilance. 096120332211432 ○
- 7 Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS. 13, ○
- 6 Patient involvement in pharmacovigilance: determinants and evolution of reporting from 2011 to 2020 in France. ○
- 5 Strategies and interventions to strengthen pharmacovigilance systems in low- and middle-income countries: a scoping review. ○
- 4 Medications Adverse Effects on Voice: Comparison Between Different Sources of Information. **2023**, ○
- 3 Analysis of drug-induced liver-related adverse event trend reporting between 1997 and 2019. ○
- 2 Analysis of Appendicitis Cases in the Japanese Adverse Drug Event Report (JADER) Database. **2023**, 46, 655-660 ○
- 1 Awareness, Actions, and Predictors of Actions on Adverse Drug Reaction Reporting among Patients Attending a Referral Hospital in Southern Highland Tanzania. **2023**, 2023, 1-7 ○